USFDA gives conditional nod to Glenmark for generic Regadenoson injection

Regadenoson injection is given during the preparation for a radiologic examination of blood flow through the heart to test for coronary artery disease.

93
USFDA
Picture: Pixabay

Last Updated on January 24, 2022 by The Health Master

Glenmark Pharmaceuticals on Monday said its US arm has received tentative approval from the country’s health regulator (USFDA) for its generic Regadenoson injection.

Regadenoson injection is given during the preparation for a radiologic examination of blood flow through the heart to test for coronary artery disease.

According to a statement, the tentative approval was granted by the United States Food & Drug Administration to Glenmark Pharmaceuticals Inc., USA (Glenmark).

It is for Regadenoson Injection at 0.4 mg/5 mL (0.08 mL) Single-Dose Prefilled Syringe.
It is the generic Lexiscan injection at 0.4 mg/5mL (0.08 mg/mL) of Astellas US Inc.

The company cited IQVIATM sales data from the 12-month period ending November 2021 and stated that the Lexiscan(r), 0.4 mg/5 mL (0.08mg/mL) market had achieved an annual sales figure of around USD 659.9 millions.

According to the company, its current portfolio includes 172 products that are authorized for distribution in the US market and 47 abbreviated drug applications (ANDAs), which are awaiting approval by the USFDA.

USFDA gives final approval to Zydus for Vigabatrin tablets

USFDA gives approval to Strides Pharma for generic Tamiflu

USFDA approves drug for the treatment of Eczema

USFDA gives nod to Glenmark for Nasal Spray to treat allergic rhinitis

USFDA gives tentative nod to Alembic for Dronedarone tablets

USFDA gives nod to Alembic Pharma for Vortioxetine tablets

New Medical Device developed for 6 tests in 60 seconds without prescription

Medicine prescriptions should be legible to avoid errors

Govt mandates QR code on labels of all APIs manufactured and imported

Govt to allow sale of these Medicines with out Prescription

ICMR approves RT-PCR Omicron detection kit

USFDA gives final approval to Zydus for Vigabatrin tablets

DCGI needs more safety data for Covaxin nod for under 12

Drug alert: 33 out of 1385 samples declared as NSQ in December 2021

Pharmaceutical Budget 2022: Expectations

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner